| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | HRMT1L5; IBP72; JBP1; SKB1; SKB1Hs; PRMT5; Skb1Hs Methyltransferase;;PRMT5 |
| WB Predicted band size | 73 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human PRMT5 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于PRMT5抗体的3篇参考文献，简要总结其内容：
1. **"PRMT5 is required for cell-cycle progression and p53 tumor suppressor function"**
- **作者**: Scoumanne A, et al.
- **摘要**: 该研究通过使用PRMT5抗体进行免疫印迹和免疫沉淀，揭示了PRMT5在细胞周期调控中的作用，并发现其缺失会导致p53依赖性细胞周期停滞，提示其在肿瘤抑制中的功能。
2. **"PRMT5 regulates epigenetic modifications and promotes survival of lung cancer cells"**
- **作者**: Yang Y, Bedford MT.
- **摘要**: 利用PRMT5抗体进行染色质免疫沉淀(ChIP)和免疫组化，研究发现PRMT5通过甲基化组蛋白H3R8和H4R3.调控肺癌相关基因表达，促进癌细胞存活和化疗耐药。
3. **"Targeting PRMT5-mediated epigenetic signaling in virus-associated cancers"**
- **作者**: Stopa N, et al.
- **摘要**: 研究使用PRMT5抗体验证病毒蛋白(如EBNA1)与PRMT5的相互作用，发现PRMT5在病毒相关癌症中通过表观遗传修饰促进肿瘤发生，为靶向治疗提供依据。
4. **"Characterization of a selective inhibitor of protein arginine methyltransferase 5 (PRMT5) with antitumor activity"**
- **作者**: Kryukov GV, et al.
- **摘要**: 通过PRMT5抗体检测抑制剂处理后细胞中对称二甲基化(SDMA)水平的变化，证实选择性PRMT5抑制剂可抑制肿瘤生长，凸显其作为癌症治疗靶点的潜力。
这些文献均通过PRMT5抗体在机制研究中发挥关键作用，涵盖肿瘤生物学、表观遗传调控及治疗开发。
**Background of PRMT5 Antibodies**
PRMT5 (Protein Arginine Methyltransferase 5) is a member of the protein arginine methyltransferase family, which catalyzes the symmetric dimethylation of arginine residues on histones and non-histone proteins. This post-translational modification plays a critical role in epigenetic regulation, RNA processing, signal transduction, and cellular differentiation. PRMT5 is involved in diverse biological processes, including gene expression control, DNA repair, cell cycle progression, and immune response. Dysregulation of PRMT5 has been linked to cancers, neurodegenerative diseases, and inflammatory disorders, making it a therapeutic target of interest.
PRMT5 antibodies are essential tools for studying its expression, localization, and function. They are widely used in techniques like Western blotting, immunoprecipitation, immunohistochemistry, and immunofluorescence to detect PRMT5 levels or assess its interaction with substrates. Specific antibodies can distinguish between methylated and unmethylated forms of PRMT5 targets, aiding in mechanistic studies. Researchers also utilize these antibodies to explore PRMT5's role in disease models, evaluate inhibitor efficacy in preclinical studies, or validate CRISPR/Cas9 knockout models.
Commercial PRMT5 antibodies are often raised against epitopes within its conserved catalytic domain or unique regions to ensure specificity. Validation includes testing in PRMT5-deficient cell lines to confirm minimal cross-reactivity. As PRMT5 inhibitors advance into clinical trials, high-quality antibodies remain crucial for both basic research and translational applications.
×
